







# Serum extracellular vesicle-derived circHIPK3 and circSMARCA5 are two novel diagnostic biomarkers for Glioblastoma Multiforme

Barbagallo D<sup>1,2</sup>, Stella M<sup>1</sup>, Falzone L<sup>1</sup>, Caponnetto A<sup>1</sup>, Gattuso G<sup>1</sup>, Barbagallo C<sup>1</sup>, Battaglia R<sup>1</sup>, Mirabella F<sup>1</sup>, Broggi G<sup>3</sup>, Altieri R<sup>2,3</sup>, Certo F<sup>2,3</sup>, Caltabiano R<sup>3</sup>, Barbagallo GMV<sup>2,3</sup>, Musumeci P<sup>4</sup>, Ragusa M<sup>1,2</sup>, Di Pietro C<sup>1</sup>, Libra M<sup>1,5,†</sup>, Purrello M<sup>1,2,†</sup>

<sup>1</sup>Dept. BIOMETEC, University of Catania, 95123 Catania, Italy, EU; <sup>2</sup>Interdisciplinary Research Centre on the Diagnosis and Therapy of Brain Tumors, University of Catania, 95123 Catania, 95123 Catania, Italy, EU; <sup>4</sup>Dept. of Physics and Astronomy, University of Catania, 95123 Catania, Italy, EU; <sup>5</sup>Research Center for Prevention, Diagnosis and Treatment of Cancer, University of Catania, 95123 Catania, Italy; †Senior Authors



# Background

- Glioblastoma multiforme (GBM) is the most frequent and deadly human brain cancer.
- Early diagnosis through non-invasive biomarkers may render GBM more easily treatable, improving the prognosis of this currently incurable disease.
- We propose the use of serum extracellular vesicle (sEV)-derived circular RNAs (circRNAs) as highly stable, minimally invasive biomarkers GBM diagnosis.




Fig. 1. Histopathologic slide demonstrating a GBM (https://emedicine.medscape.com/article/283252-overview)




Fig 2: MRI scan of glioma and GBM (http://www.aboutcancer.com/mri\_gbm.htm)



## Results

- CircSMARCA5 and circHIPK3 were significantly less abundant in sEVs from GBM patients with respect to UC (fold-change (FC) of -2.15 and -1.92, respectively) and GIII (FC of -1.75 and -1.4, respectively).
- Receiver operating characteristic curve (ROC) analysis, based on the expression of sEV-derived circSMARCA5 and circHIPK3, allowed to distinguish GBM from UC (area under the curve (AUC) 0.823 (0.667-0.979) and 0.855 (0.704 to 1.000), with a 95% confidence interval (CI), respectively).
- Multivariable ROC analysis, performed combining the expression of sEV-derived circSMARCA5 and circHIPK3 with preoperative neutrophil to lymphocyte (NLR), platelet to lymphocyte (PLR) and lymphocyte to monocyte (LMR) ratios, three known diagnostic and prognostic GBM markers, allowed to improve GBM diagnostic accuracy (AUC 0,901 (0,7912 to 1,000), 95% CI).




Figure 3. Bar graphs showing the modal diameter (nm) and concentration (particles / ml) of EVs isolated from UC (C) and GBM (D)




Figure 4. Transmission electron microscopy (TEM) of isolated sEVs positive to the tetraspanin CD81




Table 1. Candidate DE circRNAs in gliomas and their expression in sEVs from healthy individuals according to exoRBase

(<a href="http://www.exorbase.org/exoRBase/toIndex">http://www.exorbase.org/exoRBase/toIndex</a>)

(RPM = reads per million)

2

### Methods

- EVs were isolated by size exclusion chromatography from sera of 23 GBM and 5 grade 3 glioma (GIII) patients, and 10 unaffected controls (UC).
- The expression of two candidate circRNAs (circSMARCA5 and circHIPK3)
   was assayed by droplet digital PCR (ddPCR).



1. Blood sampling

2. Serum preparation

3. Serum extracellular vesicles isolation






Figure 5. CircSMARCA5 and circHIPK3 were significantly less abundant in sEVs from GBM patients with respect to UC and GIII




Figure 6. Correlogram showing correlations between the expression of sEV-derived circSMARCA5 and circHIPK3 and hematological data




Figure 7. Univariable and multivariable receiver operating characteristic (ROC) curve analysis



# Conclusions

• Our data convincingly suggest sEV-derived circSMARCA5 and circHIPK3 as new good diagnostic GBM biomarkers, especially when combined with preoperative

NLR, PLR and LMR data.

#### Acknowledgements

This research was partially supported by the Lega Italiana per la Lotta contro i Tumori (LILT), by "PIAno di inCEntivi per la RIcerca (PIA.CE.RI.) di Ateneo 2020/2022"—"linea di intervento 3, STARTING GRANT" (Project EPIGLI)

and "linea Open Access", from UniCT.

Nano Rome, 19-23 September 2022 Innovation
Conference & Exhibition

Barbagallo D. et al., 2018, IJMS,
 doi: 10.3390/ijms19020480
 Barbagallo D. et al., 2019, Cancers,
 doi: 10.3390/cancers11020194
 Barbagallo D et al., 2021, IJMS,
 doi: 10.3390/ijms22041678

doi: 10.3390/ijms22041678
4) Stella M. et al., 2021, *Pharmaceuticals*, doi: 10.3390/ph14070618

References



Davide Barbagallo dbarbaga@unict.it